New Hope for MDR/XDR TB with Poly Herbal Immune Modulator Product

Tuberculosis (TB) remains a significant public health issue globally, and India carries the highest burden of TB cases in the world. Multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) are more severe forms of TB that are resistant to first-line and second-line treatments, respectively. These forms of TB present considerable challenges to public health due to their complexity in treatment and higher mortality rates. This essay discusses the prevalence, challenges, and treatment procedures of MDR and XDR-TB in India, referencing various Indian journals and studies.

Socio-economic Factors

Socioeconomic factors further exacerbate the TB crisis in India. Poverty, malnutrition, and overcrowded living conditions contribute to the spread of TB and hinder effective treatment. Patients often face financial barriers to accessing healthcare and completing treatment regimens, as noted in a study from the Indian Journal of Community Medicine (2018).

Regular monitoring and patient support are critical components of successful TB treatment. Directly Observed Treatment, Short-course (DOTS) ensures that patients adhere to their medication regimens under the supervision of healthcare workers. The Journal of Family Medicine and Primary Care (2018) emphasizes the importance of DOTS in reducing treatment default rates and preventing the emergence of further drug resistance.

Multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) pose significant challenges to global health, particularly in high-burden countries like India. The conventional treatment regimens for these forms of TB are lengthy, toxic, and often result in suboptimal outcomes. Recently, there has been increasing interest in the use of immunomodulators as adjuvant therapy to improve treatment success rates. This explores the role of immunomodulators in the treatment of MDR and XDR TB, highlighting evidence from Indian studies on their efficacy and impact on treatment outcomes.

Role of Immunomodulators

Immunomodulators are agents that modify the immune response, enhancing the body's ability to fight infections. In the context of MDR and XDR TB, they are used as adjuvant therapy to conventional antimicrobial treatment. Several immunomodulators have been studied for their potential benefits in TB treatment, including cytokines (such as interferon-gamma), vitamins (like vitamin D), and herbal formulations.

Adjunctive Benefits in Drug-Resistant TB

Indian studies have demonstrated that immunomodulators can improve the efficacy of existing drug regimens. For instance, a study published in the Indian Journal of Medical Research highlighted that the addition of certain immunomodulators to standard anti-TB therapy resulted in better sputum conversion rates and reduced treatment duration for MDR TB patients.

1.?????? Herbal Immunomodulators: 1.?????? The product VIRULINA R-Natural Solutions (VLR-NS) (As 5, 10, 20, 50, 100 mg/ml suspension) was evaluated for immunomodulatory activity, using the PMN function testIn vitro phagocytosis test:VLR-NSwas evaluated at concentrations of 5, 10 and 20, 50 and 100 mg/ml. It showed significant activity at concentrations of 100 mg/ml. As neutrophils form the first line of host defense by virtue of their ability to phagocytose invading microorganisms, they have a major role in modulating the immune function. The stimulation of neutrophils results in an increase in the immediate cellular immune response. The results of the in vitro PMN function test showed a significant increase in the percentage phagocytosis and phagocytic index for successive methanol and water extracts. This indicates that VLR-NS enhances the phagocytic efficacy of the PMN cells at 100 mg/ml by causing more engulfment of the Candida cells versus control, thereby stimulating a non-specific immune response.

As the VLR-NS showed promising immunostimulant activity in the in vitro test, it was taken up for in vivo animal studies.

Antibody molecules which are secreted by plasma cells mediate the humoral immune response. Virulina showed an increase in the hemagglutination titer at doses of 100 mg/kg and 200 mg/kg in animal studies. This augmentation of the humoral response to SRBC indicated an enhanced responsiveness of the macrophages and T and B lymphocyte subsets involved in antibody synthesis.[11-15

VLR-NSprobably stimulates lymphocyte proliferation, which in turn leads to production of cytokines that activate other immune cells such as B cells, antigen-presenting cells and other T cells. Studies such as the lymphocyte transformation test and cytokine studies are currently underway to understand the exact mechanism for the observed immunostimulation.

VLR-NSprobably stimulates lymphocyte proliferation, which in turn leads to production of cytokines that activate other immune cells such as B cells, antigen-presenting cells and other T cells. Studies such as the lymphocyte transformation test and cytokine studies are currently underway to understand the exact mechanism for the observed immunostimulation.

VLR-NSwas found to have a significant immunostimulant activity on both the specific and non-specific immune mechanisms.

Looking for Co Sponsor in the said project and if collaborator is from business community will have a preference. Said product has already crossed over many research line to have validation including Anti Viral Study with Virology centre.

We are looking for business partners also on the products.Hospitals/Doctors are welcome

Dr Anil Sharma 9322935092 or mail me proposal at : [email protected]

To know more can log on to : www.nsnpl2health.com

www.virulina.com